The United States has launched an investigation into Germany to determine whether there has been underpayment for innovative pharmaceutical products affecting trade in the US.
"This investigation will seek to determine whether persistent underpayment for innovative pharmaceutical products by Germany is unreasonable or discriminatory and burdens or restricts US commerce," said US Trade Representative Jamieson Greer.
He said the investigation under Section 301 of the Trade Act of 1974 came after "months of meaningful discussions with our German partners in an effort to resolve this issue."
What else did Greer say?
"President Trump has made clear that American patients should not be shouldering a disproportionate share of global pharmaceutical research and development," said Greer.
